Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3p6GMf5
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/ubqxhkvmY7 https://t.co/NAAD62XjpY
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: Rinvoq FDA Approved for Active Psoriatic Arthritis
https://t.co/1ysUj0GUqw https://t.co/fmDA9UyFY3
Mithu Maheswaranathan, MD MithuRheum
4 years 9 months ago
🆕 Myositis Specific Antibodies (MSAs): Clinical Features and Treatment for #Myositis/IIM 💪🏽
💪🏻Proximal Muscle Weakness
🫁 Interstitial Lung Disease
🤚🏽 Cutaneous [Dermatomyositis]
#RheumTwitter #DermTwitter #PulmTwitter #MedEd https://t.co/TCwpLI1yNr
Pedro Machado pedrommcmachado
4 years 9 months ago
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations https://t.co/ljqEjZNwx5 https://t.co/8fVIskV3gd
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: Increased risk death in 310 scleroderma pts: 63 diffuse SSc, 279 limited dz & 33 sine scleroderma (SMR = 1.88). Reduced survival at 10 yrs (78%) & 15 yrs(61%). 69 deaths, 46% in diffuse PSS - due to ILD, PHA, and GI involvement https://t.co/OZg8QamhEB
Dr. John Cush RheumNow
4 years 9 months ago
There's good news and bad news in rheumatology fellowship matching for 2022. There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. All that a more on this week’s podcast.
https://t.co/gklOK2S1QC https://t.co/QrYg1QZKhJ
Dr. John Cush RheumNow
4 years 9 months ago
Certain Cancers Increased with Autoimmune Diseases
Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions?
https://t.co/00SZ9nSX0I https://t.co/yXGehFTjF6
Dr. John Cush RheumNow
4 years 9 months ago
CDC Panel Recommends mRNA COVID Vaccines Over J&J Vaccine
The CDC has recommended the two authorized mRNA COVID-19 vaccines over J&J adenovirus COVID-19 vaccine, primarily due to the rare reports of thrombosis with thrombocytopenia syndrome (TTS).
https://t.co/qjZlzE7top https://t.co/UKsLbtRNv2
Dr. John Cush RheumNow
4 years 9 months ago
Telemedicine? Surveys (patients=1340, MD=111) & interviews (pts= 31, MD= 29) April 2021 and July 2021. Results suggest pts and MDs prefer F2F over Telemedicine almost all categories. Some negatives may be due to the pandemic https://t.co/TdOORCfx6l
Dr. John Cush RheumNow
4 years 9 months ago
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis
The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced.
https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX
Dr. John Cush RheumNow
4 years 9 months ago
UCB released results of BE MOBILE 2 Phase 3 study of bimekizumab, a dual IL-17A and F inhibitor, in active ankylosing spondylitis. Showing at wk 16 superiority of BIM over PBO in ASAS40, BASDAI, ASDAS, ASAS partial remission https://t.co/Jt8mpxUCv0 https://t.co/T5QpJu8n6r
There's good news and bad news in rheumatology fellowship matching for 2022. There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine.
Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.
Dr. John Cush RheumNow
4 years 9 months ago
CV mortality with infection & inflammation studied using CDC database; From 1999 to 2018 CV mortality decreased in general population (40.9 to 30.6%) but increased w/ HCV (7.0 -10.2%) & HIV (1.9 to 6.7%); decreased in plateaud in IBD, PSO, RA, and SLE https://t.co/Oiv92xRs6W
